DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

A-protein Levels in Adult and Pediatric Brain Tumor Patients

Completed

Conditions: Malignant Childhood Central Nervous System Neoplasm

Interventions: Other: A PROTEIN level

First Posted Date: 2005-09-14

Last Posted Date: 2016-11-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 54

Registration Number: NCT00165542

Locations: 🇺🇸
Dana Farber Cancer Institite, Boston, Massachusetts, United States

Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate

Phase 2

Terminated

Conditions: Pleural Mesothelioma
Malignant Pleural Mesothelioma

Interventions: Drug: Cisplatin
Drug: Sodium Thiosulfate
Drug: ALIMTA

First Posted Date: 2005-09-14

Last Posted Date: 2016-09-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00165503

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer

Phase 2

Completed

Conditions: Early-Stage Breast Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2017-06-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT00165243

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease

Completed

Conditions: Breast Cancer
Hodgkin's Disease

First Posted Date: 2005-09-14

Last Posted Date: 2019-05-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 148

Registration Number: NCT00165412

Locations: 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma
Relapsed Multiple Myeloma
Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: CC-5013

First Posted Date: 2005-09-12

Last Posted Date: 2016-01-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 58

Registration Number: NCT00153933

Locations: 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Winship Cancer Center, Atlanta, Georgia, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

Phase 2

Completed

Conditions: Hemoglobinopathies
Sickle Cell Disease
Thalassemia

First Posted Date: 2005-09-12

Last Posted Date: 2013-07-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00153985

Locations: 🇺🇸
Winship Cancer Institute-Emory University, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations

Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: bortezomib

First Posted Date: 2005-09-12

Last Posted Date: 2019-06-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 66

Registration Number: NCT00153920

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States

and more 3 locations

Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2005-09-12

Last Posted Date: 2013-02-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00153907

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Effects of Exercise Intervention on Insulin Levels in Breast Cancer Survivors

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Strength training
Behavioral: Endurance training

First Posted Date: 2005-09-12

Last Posted Date: 2016-06-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT00153894

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Preoperative Herceptin and Navelbine for Breast Cancer

Phase 2

Completed

Conditions: Stage III Breast Cancer
Breast Cancer
Stage II Breast Cancer

Interventions: Drug: Herceptin
Drug: Navelbine
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel

First Posted Date: 2005-09-08

Last Posted Date: 2019-01-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 49

Registration Number: NCT00148681

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy